Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib
Abstract This is the first case report of a non‐small‐cell lung cancer (NSCLC) patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del treated with first‐line alectinib. Approximately 5% of NSCLC patients are reported to have anaplastic lymphoma kinase (ALK) rearrangements, and among these EML4‐ALK...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-11-01
|
| Col·lecció: | Thoracic Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1111/1759-7714.15397 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
